SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the first report describing the effects of lectin-pathway inhibition by narsoplimab on urinary complement levels in ...
The study of immune inflammatory responses centers on the intricate molecular pathways that both initiate and modulate these processes. Inflammation is ...
Nipocalimab might lower the concentration of anti-acetylcholine receptor antibodies in people with generalized myasthenia gravis, a study shows. PHOENIX, Arizona—Nipocalimab might lower the ...
With Alzheimer’s disease therapies finally reaching the market and hundreds of active clinical trials for therapies and diagnostics, it seems like every week brings another potential avenue to explore ...
Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...
These findings suggest complement protein levels may be an important biomarker for type 1 diabetes. Disruption of the complement system appears to precede the onset of islet autoimmunity (IA), making ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results